BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25163420)

  • 1. Comparison of [¹¹C]choline ([¹¹C]CHO) and S(+)-β-methyl-[¹¹C]choline ([¹¹C]SMC) as imaging probes for prostate cancer in a PC-3 prostate cancer xenograft model.
    Schwarzenböck SM; Gertz J; Souvatzoglou M; Kurth J; Sachs D; Nawroth R; Treiber U; Schuster T; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Henriksen G; Wester HJ; Krause BJ
    Mol Imaging Biol; 2015 Apr; 17(2):248-56. PubMed ID: 25163420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.
    Schwarzenböck SM; Schmeja P; Kurth J; Souvatzoglou M; Nawroth R; Treiber U; Kundt G; Berndt S; Graham K; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Dinkelborg L; Wester HJ; Krause BJ
    Mol Imaging Biol; 2016 Jun; 18(3):393-401. PubMed ID: 26483088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model.
    Krause BJ; Souvatzoglou M; Herrmann K; Weber AW; Schuster T; Buck AK; Nawroth R; Weirich G; Treiber U; Wester HJ; Ziegler SI; Senekowitsch-Schmidtke R; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1861-8. PubMed ID: 20512572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [[¹¹C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model].
    Schwarzenböck S; Sachs D; Souvatzoglou M; Schuster T; Nawroth R; Weirich G; Treiber U; Wester HJ; Ziegler S; Schwaiger M; Senekowitsch-Schmidtke R; Krause BJ
    Nuklearmedizin; 2013; 52(4):141-7. PubMed ID: 23396481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.
    Kukuk D; Reischl G; Raguin O; Wiehr S; Judenhofer MS; Calaminus C; Honndorf VS; Quintanilla-Martinez L; Schönberger T; Duchamp O; Machulla HJ; Pichler BJ
    J Nucl Med; 2011 Oct; 52(10):1654-63. PubMed ID: 21859811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[18F]fluorocholine ([18F]dOC).
    Henriksen G; Herz M; Hauser A; Schwaiger M; Wester HJ
    Nucl Med Biol; 2004 Oct; 31(7):851-8. PubMed ID: 15464386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models.
    Zheng QH; Gardner TA; Raikwar S; Kao C; Stone KL; Martinez TD; Mock BH; Fei X; Wang JQ; Hutchins GD
    Bioorg Med Chem; 2004 Jun; 12(11):2887-93. PubMed ID: 15142549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.
    DeGrado TR; Coleman RE; Wang S; Baldwin SW; Orr MD; Robertson CN; Polascik TJ; Price DT
    Cancer Res; 2001 Jan; 61(1):110-7. PubMed ID: 11196147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [11C]choline PET/CT impacts treatment decision making in patients with prostate cancer referred for radiotherapy.
    Jereczek-Fossa BA; Rodari M; Bonora M; Fanti P; Fodor C; Pepe G; Lopci E; Zerini D; Vischioni B; Baroni G; Matei DV; De Cobelli O; Chiti A; Orecchia R
    Clin Genitourin Cancer; 2014 Jun; 12(3):155-9. PubMed ID: 24331577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A; Zechmann CM; Malcher A; Eder M; Eisenhut M; Linhart HG; Holland-Letz T; Hadaschik BA; Giesel FL; Debus J; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):11-20. PubMed ID: 24072344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.
    Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H
    Mol Imaging Biol; 2017 Dec; 19(6):915-922. PubMed ID: 28924629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
    Price DT; Coleman RE; Liao RP; Robertson CN; Polascik TJ; DeGrado TR
    J Urol; 2002 Jul; 168(1):273-80. PubMed ID: 12050555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
    von Eyben FE; Kairemo K
    Ann Nucl Med; 2016 Jul; 30(6):385-92. PubMed ID: 27173771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of deuterated 18F- and 11C-labeled choline analogs for cancer detection by positron emission tomography.
    Witney TH; Alam IS; Turton DR; Smith G; Carroll L; Brickute D; Twyman FJ; Nguyen QD; Tomasi G; Awais RO; Aboagye EO
    Clin Cancer Res; 2012 Feb; 18(4):1063-72. PubMed ID: 22235095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Evaluation of
    Piert M; Shao X; Raffel D; Davenport MS; Montgomery J; Kunju LP; Hockley BG; Siddiqui J; Scott PJH; Chinnaiyan AM; Rajendiran T
    J Nucl Med; 2017 Aug; 58(8):1216-1223. PubMed ID: 28302759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates.
    Krause BJ; Souvatzoglou M; Treiber U
    Urol Oncol; 2013 May; 31(4):427-35. PubMed ID: 21388835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.
    Schroeder RP; van Weerden WM; Krenning EP; Bangma CH; Berndsen S; Grievink-de Ligt CH; Groen HC; Reneman S; de Blois E; Breeman WA; de Jong M
    Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1257-66. PubMed ID: 21431398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging.
    Hara T; Kosaka N; Kishi H
    J Nucl Med; 2002 Feb; 43(2):187-99. PubMed ID: 11850483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.